{
    "title": "105_s2015",
    "content": "The Act titled \"New Medications to Treat Addiction Act of 1998\" authorizes appropriations for medication development programs for fiscal years 1999 through 2001. Additionally, there are patent protections for pharmacotherapies included in the Act. SEC. 201 of the Act amends the Federal Food, Drug, and Cosmetic Act to recommend investigation of drugs for the treatment of addiction to illegal drugs. It also updates the designation of drugs. Section 526(a) of the Federal Food, Drug, and Cosmetic Act is amended to include treatment of addiction to illegal drugs in the criteria for drug investigation and designation. The amendment to Section 526(a) of the Federal Food, Drug, and Cosmetic Act includes the definition of treatment for addiction to illegal drugs, specifying that it involves the use of pharmacological agents or medications to reduce cravings for the drug in individuals who are endangering public health or are unable to control their addiction. The term 'illegal drug' refers to controlled substances listed in schedules I-V, and treatment for addiction involves using pharmacological agents to reduce cravings and help individuals unable to control their addiction. Controlled substances are identified under schedules I-V in the Controlled Substances Act. SEC. 203 amends the Federal Food, Drug, and Cosmetic Act to include treatment of addiction to illegal drugs. SEC. 204 focuses on open protocols for drug investigations. SEC. 204 amends the Federal Food, Drug, and Cosmetic Act to include investigations for the treatment of addiction to illegal drugs. The subchapter heading and section headings of the Federal Food, Drug, and Cosmetic Act are amended to include treatment of addiction to illegal drugs. Fees for rare diseases or conditions are also amended to include treatment of addiction. The Federal Food, Drug, and Cosmetic Act is amended to include treatment of addiction to illegal drugs in fees for rare diseases or conditions. TITLE III--ENCOURAGING PRIVATE SECTOR DEVELOPMENT OF PHARMACOTHERAPIES\n\nSEC. 301. DEVELOPMENT, MANUFACTURE, AND PROCUREMENT OF DRUGS FOR THE TREATMENT OF ADDICTION TO ILLEGAL DRUGS. Amends Chapter V of the Federal Food, Drug, and Cosmetic Act to include criteria for acceptable drug treatment for cocaine and heroin addictions. The Secretary, in collaboration with the Institute of Medicine, will establish criteria for acceptable drugs to treat cocaine and heroin addiction. These criteria will be used for contracts or licensing agreements under section 572. The requirements for a drug include approval by the Secretary after the enactment of this section and the completion of a performance-based test. The performance-based test for drugs to treat cocaine and heroin addiction involves randomly selected test and control groups, comparing long-term addiction levels, and demonstrating effectiveness through participants' willingness to take the drug. Participants in the drug addiction test showed willingness to continue treatment with the drug, refrained from using cocaine or heroin for a longer period compared to current treatments, and the drug should have a reasonable production cost. The criteria for drug production cost shall be reviewed by congressional committees before publication in the Federal Register. SEC. 572. PURCHASE OF PATENT RIGHTS FOR DRUG DEVELOPMENT. The patent owner of a drug to treat addiction to cocaine or heroin can submit an application to the Secretary to sell patent rights or enter into an exclusive licensing agreement for manufacturing and distribution. The application must meet requirements set by the Secretary. The Secretary may enter into a contract or licensing agreement with a patent owner for a drug that meets specified criteria. This includes one contract for treating cocaine addiction and one for treating heroin addiction. The Secretary may enter into contracts or licensing agreements with patent owners for drugs to treat addiction to cocaine and heroin. The maximum payment for a drug to treat cocaine addiction is $100,000,000, while for heroin addiction, it is $50,000,000. Transfer of rights under these contracts and agreements is also allowed. The Secretary can enter contracts or licensing agreements with patent owners for drugs treating cocaine and heroin addiction. These agreements transfer exclusive rights to the Secretary for making, using, and selling the patented drug in the U.S., along with foreign patent rights, manufacturing process patents, and confidential information related to drug development. The Secretary can enter licensing agreements to purchase exclusive rights for drugs treating cocaine and heroin addiction. This includes the right to make, use, and sell the patented drug in the U.S., use patented manufacturing processes, and access confidential information related to drug development. \"SEC. 573. PLAN FOR MANUFACTURE AND DEVELOPMENT.\" The Secretary must develop a plan for manufacturing and distributing a drug within 90 days of acquiring patent rights or entering into a licensing agreement. The plan includes procedures for licensing agreements, drug availability for addiction treatment, setting sale prices, and guidelines for the use of Federal funds. The Secretary must develop a plan for manufacturing and distributing a drug within 90 days of acquiring patent rights or entering into a licensing agreement. Federal law on procurements and licensing agreements applies to the plan. Upon completion, the Secretary notifies relevant committees and publishes the plan for public comment. The Secretary must develop a plan for manufacturing and distributing a drug within 90 days of acquiring patent rights or entering into a licensing agreement. The plan is open for public comment for 30 days, with the final plan published within 60 days after the comment period. Judicial review is not applicable to any agency action related to the plan. The Secretary may promulgate regulations to carry out the plan. Authorization of appropriations for fiscal years 1999 through 2001 is provided for this subchapter."
}